News
Comphya Closes Oversubscribed CHF 7.5 Million Series A Round
Comphya SA, a Vaud-based clinical-stage MedTech company pioneering the first implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication, announced the closing of an oversubscribed Series A financing round. Including the conversion of existing convertible loans, the round brings Comphya’s total equity raised to CHF 7.5 million (~USD 8.4 million). “We are…
Read MoreHilo by Aktiia Received FDA 510(k) Clearance for its Blood Pressure Monitor Wristband
The CSEM spinoff Aktiia has received FDA 510(k) clearance for its over-the-counter cuffless blood pressure monitor, G0 Blood Pressure Monitoring System, also known as the Hilo Band. Thi wearable uses an optical sensor to collect data from one’s wrist. The Hilo by Aktiia wrist wearable is one of a kind as it collects one’s blood…
Read MoreVenture Leaders Medtech Presents the 2025 Cohort
Ten promising startups have been named to the Swiss National Medtech Team 2025 and will travel to Boston from 28 September to 3 October to pitch to investors, expand their network, and meet industry leaders. The Venture Leaders Medtech programme is organized by Venturelab, with the support of EPFL, ETH Zurich, Hansjörg Wyss, Helbling…
Read MoreMBA in Biotech Management
The Geneva Business School launches next fall a MBA in Biotech Management at Campus Biotech Geneva. This MBA equips students with both scientific fluency and strategic business acumen. In a rapidly evolving industry where scientific breakthroughs must translate into real-world impact, the need for visionary leadership has never been greater. The MBA in Biotech…
Read MoreStalicla Secures CHF 2 Million Financing Led by Addex Therapeutics
STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, announced the successful closing of a CHF 2 million financing led by Addex Therapeutics. This financing will sustain operations and program development in neurodevelopmental disorders as Stalicla prepares for its upcoming Series C and the partnering of key programs.…
Read MoreTimeline® and Cellcosmet Get a Science of Skin Award
The Science of Skin Awards, hosted by Skincare Anarchy LLC, stand as a global benchmark for scientific integrity and innovation in skincare. Each year, only ten brands are selected for this prestigious honor, and two Swiss brands, Timeline® and Cellcosmet are among the winners. The Science of Skin Awards recognize skincare companies that leverage…
Read MoreTwo UNIGE Life Sciences Projects Get a CHF 100’000 innoLIFE Grant
Two UNIGE scientists, Sanae El Harane from the Department of Medicine, and Maude Rolland, from the Department of Surgery received a CHF 100’000 innoLIFE grant to pursue their research. Turning academic breakthroughs into real-world healthcare solutions is no small feat. In fields like pharma, biotech, and medtech—where regulation is stringent and the path to…
Read MoreAdiposs Raises CHF 4 million in Series A
Adiposs SA, a Geneva-based clinical-stage Swiss life sciences company announced the successful closing of a CHF 4 million Series A financing round. The round was syndicated by Swiss and Taiwanese VC firms, European family offices and high-net-worth individual investors. Adiposs is pioneering the development of the first imaging product for brown fat designed to…
Read MoreInTeeth Receives a CHF 100,000 FIF Seed Loan
InTeeth, a University of Geneva spinoff has developed a patented InLiner, the first-ever lingual aligner that is fixed behind the teeth. Three high-potential projects from Geneva have been awarded funding through the FONGIT Innovation Fund (FIF), reinforcing the canton’s support for breakthrough technologies in life sciences and precision engineering. InTeeth received a CHF 100,000…
Read MoreBeech Biotech Awarded $1.9 million by the Gates Foundation
Beech Biotech, a Lausanne-based biopharmaceutical company creating “Mother only” monoclonals to treat complications of pregnancy, has been awarded a $1.9 million grant by the Gates Foundation for the development of its breakthrough therapeutic approach in preeclampsia. Preeclampsia is a leading cause worldwide of maternal morbidity and mortality, premature birth, stillbirth, and neonatal death. Each…
Read More